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Abstract
Background
Antiretroviral therapy has shown to be effective in reducing morbidity and mortality in
patients infected with HIV for the past couples of decades. However, there remains a need
to better understand the characteristics of long-term treatment outcomes in resource poor
settings. The main aim of this study was to determine and compare the long-term response
of patients on nevirapine and efavirenz based first line antiretroviral therapy regimen in
Ethiopia.
Methods
Hospital based retrospective cohort study was conducted from January 2009 to December
2013 at University hospital located in Northwest Ethiopia. Human subject research approval
for this study was received from University of Gondar Research Ethics Committee and the
medical director of the hospital. Cox-proportional hazards model was used to assess the
effect of baseline covariates on composite outcome and a semi-parametric mixed effect
model was used to investigate CD4 counts response to treatments.
Results
A total of 2386 HIV/AIDS naive patients were included in this study. Nearly one-in-four
patients experienced the events, of which death, lost to follow up, treatment substitution and
discontinuation of Non-Nucleoside Reverse Transcriptase Inhibitors(NNRTI) accounted: 99
(26.8%), 122 (33.0%), 137 (37.0%) and 12 (3.2%), respectively. The hazard of composite
outcome on nevirapine compared with efavirenz was 1.02(95%CI: 0.52-1.99) with p-value =
0.96. Similarly, the hazard of composite outcome on tenofovir and stavudine compared with
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zidovudine were 1.87 (95%CI: 1.52-2.32), p-value < 0.0001 and 1.72(95% CI: 1.22-2.32),
p-value = 0.002, respectively. The rate of CD4 increase in response to treatment was high
during the first 10 months and stabilized later.
Conclusions
This study revealed that treatment responses were comparable whether nevirapine or efa-
virenz was chosen to initiate antiretroviral therapy for HIV/AIDS patients in Ethiopia. There
was significant difference on risk of composite outcome between patients who were initiated
with Tenofovir containing ART regimen compared with zidovudine after controlling for
NNRTI drug combinations.
Introduction
The scale-up of antiretroviral therapy (ART) for HIV/AIDS patients in resource-limited set-
tings has been one of the largest public health operations in many African countries, and by
the end of 2013 more than 11.7 million people were receiving ART in low and middle-income
countries [1, 2]. ART has been shown to be effective in reducing morbidity and mortality in
patients infected with HIV [3, 4]. It averts 5.5 million deaths in low and middle income coun-
tries from the peak in 1995 until 2013. Sub-Saharan Africa accounted for most of those lives
[5]. The goal of ART is to attain maximal and durable suppression of the viral replication and
prolong diseases free survival [6].
The revision of the World Health Organization (WHO) HIV-treatment guidelines in 2010
brought several changes to the management of HIV-infected patients [7]. Among them was a
statement about progressing to less toxic antiretroviral drugs in first-line regimens. Since 2006,
WHO has recommended in its HIV/AIDS treatment guidelines that treatment providers
begin moving away from the drug Stavudine (d4t) because of its long-term irreversible side
effects, and instead to use either Tenofovir (TDF) or zidovudine (AZT) as Nucleotide Reverse
Transcriptase Inhibitor (NRTI) backbone [8]. European Medicines Agency recommended
that, in view of its long-term toxicities, d4t be used for as short time as possible and only when
no appropriate alternatives exist [9].
The effectiveness of ART has been assessed by clinical observations, CD4 cell counts and
determination of plasma viral load [10]. The Non-Nucleoside Reverse Transcriptase Inhibitors
(NNRTIs) are drugs choices for initial ART for HIV infection. Studies in resource-rich settings
revealed that efavirenz (EFV) containing regimen has better treatment outcomes than nevira-
pine (NVP) containing regimen [11, 12]. A randomized clinical trial in India [13] also showed
that regimen containing nevirapine (NVP) was inferior and was associated with more frequent
virologic failure and death. This was supported in some resource-poor settings including Swa-
ziland, Zambia and Botswana as well [14–16]. However, there exist evidence in resource-poor
settings that shows as there was no difference between EFV and NVP in the long-run [17–19].
In the national treatment guideline of Ethiopia 2010, the first-line ART contains four NRTIs
backbone (Stavudine (d4t), zidovudine (AZT), Abacavir (ABC) and Tenofovir (TDF)) plus
lamivudine (3TC) and two NNRTI drugs (efavirenz (EFV) or nevirapine (NVP)) [10]. The
combination regimens which have been used most frequently in Ethiopia are d4t-3TC-EFV,
d4t-3TC-NVP, AZT-3TC-EFV, AZT-3TC-NVP, TDF-3TC-EFV, or TDF-3TC-NVP. When
the patient is unable to tolerate the side-effect due to toxicity, the offending drug can be substi-
tute with another drug that does not have the same side-effect [20]. Whereas, patients switch to
Outcome and CD4 Response to Antiretroviral Treatment
PLOS ONE | DOI:10.1371/journal.pone.0168323 December 20, 2016 2 / 18
second-line regimen when the first-line regimen failed due to different reasons. A failure in
treatment is measured in three ways: (1) clinical-when new or recurrent WHO stage 4 condi-
tion, (2) immunological-when persistent CD4 level below 100 or 50% fall from on-treatment
peak value and (3) virological-when plasma viral load above 10,000 copies/ml in duplicates
after six months on ART [10].
The choice of treatment combinations for HIV/AIDS patients to initiate ART depends on
cost and efficacy. Thus, knowing the long-term treatment outcomes of more costly drugs is
very decisive for decision making in resource limited nations. In this study we aim to deter-
mine the long-term outcomes of first-line ART drugs and rate of change in log-CD4 cell
counts in response to antiretroviral treatments. Furthermore, the effect of treatment choices at
the initiation on CD4 evolution was compared and tested as well. This paper is organized as
follows. In Section 2, we present the methods. In Section 3, present the result of survival and
longitudinal models. In Section 4, the finding of the two approaches were discussed and con-
cluding remarks were given.
Methods
Study Population
Gondar University hospital ART clinic started treating HIV/AIDS patients as part of the
National AIDS control program since 2005. At the same time ART was started to be provided
for free in the selected hospitals in the country, Gondar University hospital is one of these hos-
pitals. As a result, patients were referred to Gondar University hospital from many areas in
Northwest Ethiopia.
The study included ART naïve patients aged 15 years-old who initiated ART containing
TDF, d4t, or AZT as NRTI backbone with NVP and EFV as NNRTI drugs between 2009 and
2013. In total, following the inclusion criteria, 2386 patients included in this study. Data on
patients were recorded in patients’ chart and entered into access database which was designed
for this purpose. Baseline characteristics such as sex, age, weight, WHO staging and functional
status were collected when the patient enrolled in the clinic. Whilst clinical variables such as
CD4 cell counts, and regimen were collected every 6 months subsequently depending on the
progress of the patient. In some cases, patient’s visit might be taken at irregular time due to dif-
ferent reasons such as diseases progression, toxicity or opportunistic infections. The criteria
for initiating ART in Ethiopia followed WHO guideline [7], with an adjustment of CD4
threshold from 200 to 350 cell/mm3 in 2010.
Data and Study Variables
Data for the study were accessed from ART clinic database which had been collected from
HIV/AIDS patients who initiated ART from January 2009 to December 2013. As mentioned
above, data were recorded in the patients’ chart by health professional at enrollment and at
each visit. Since 2009 the hospital used electronic recording system (database) prepared for
this purpose. The information collected by the health professional from the patient were sent
to the data manager who entered the data into the computer. Information on treatment substi-
tution, treatment discontinuations, death, lost to follow up and transferred out were obtained
from hospital records.
For this study, NNRTI substitution, treatment discontinuation, transferred out, lost to follow
up and death were defined as follows: NNRTI substitution is modifying NNRTI drugs of the
original regimen for any reason. treatment discontinuation is when the patient changed his/her
first-line regimen to second-line regimen. Lost to follow up was defined as missing a clinic
appointment for more than three months without further attendance at clinic. Transferred out
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was defined as transfer of patients to other ART clinic with all the history/records. Death was
defined as confirmed deaths from medical records or verbal confirmation of death by relatives
or friends. Patients who had at least two CD4 counts (two visits for those who experienced the
event) were included for the study. Information on baseline characteristics were obtained
from registry in the database. Whereas,follow-up variables were accessed from ART refill. The
data were closed for analysis on December 31, 2013.
Data quality Control. The ART clinic of Gondar University hospital has been using data-
base to enter information of the patients starting from the first visit. It was developed by infor-
mation technologist and well tested before used for data entry in the hospital. Well trained
data entry clerks employed by the hospital perform the data enter. The entry process is super-
vised by the data manager for completeness and consistency in daily bases. The data for this
study was accessed from this database. When data on important variable (CD4 counts, regi-
men, and last patient status), is missed in the database, it was retrieved from patients’ chart at
the chart room.
Data Analysis Methods
Data analysis for time to event outcomes. We compared patient characteristics at ART
initiation by initial NNRTI treatment groups (EFV or NVP) using chi-square test for categori-
cal covariates and Wilcoxon rank sum test for continuous covariates. There were different
responses to ART treatment. A composite endpoint which represents different responses to
ART treatment was defined and analyzed as time to event endpoint. These include drug substi-
tution, lost to follow up, treatment discontinuation, and death. Three types of survival analysis
were considered; primary analysis (NNRTI substitution and lost to follow up were treated as
censored), two sensitivity analysis (NNRTI substitution and/or lost to follow up were treated
as event).
For the primary outcome, time to the first occurrence of any of the outcome measures was
calculated by subtracting the date of the event from the date of initiation of ART. Patients were
censored if death was not observed until the time of the last visit for patients who were lost and
December 31, 2013 for patients who were alive. Note that we assessed NNRTI substitution and
discontinuation as an event [21]. Discontinuation of NNRTI was defined as discontinuation of
either NVP or EFV due to toxicity, or patient or physician preference.
Log-rank test was used to compare between groups of baseline categorical variables. Cox-
regression analysis was used to identify predictors for the time to event outcomes. Baseline
covariates such as sex, age ( 40 versus<40 years), WHO clinical stage (IV or II versus I or
II), CD4 cell counts (<200 versus200), calendar year (before 2010 versus since 2010), NRTI
backbones (d4t plus 3TC, AZT plus 3TC or TDF plus 3TC) and NNRTI drugs (EFV versus
NVP) were considered. The categorization of numeric variables was done based on other pre-
vious studies [21] [22] for comparison purpose. Similarly, Cox-regression analysis was used to
compare the baseline covariates for their risk of composite outcome [23]. The hazard ratio
with 95% confidence interval was used to test statistical significant association. A detail discus-
sion about the cox-regression can be referred in the supporting information section (S1
Appendix).
Data analysis for Immunological outcomes. Treatment effects on the CD4 cell counts
evolution varies over time and it is expected that repeated measurements taken on the same
subject to be correlated. A linear mixed-effect models [24] can be used to account for this
types of correlations [25]. However, the trajectory of CD4 cell counts over time is not purely
linear, but nonlinear. To investigate the effect of treatment on the change in CD4 cell counts
over time, we used Semi-parametric mixed effects model [26] which is a data driven approach.
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Such a model can capture both linear and non linear trend in the data. It allows smoothing
with respect to time. For this model, log transformed CD4 cell counts over time was fitted
using the R package mgcv. Furthermore, the first order derivatives for each treatment groups
were plotted with 95% confidence band in order to determine the effect of treatments on the
rate of change in log CD4 cell counts over time. An elaborate discussion about the semi-
parametric mixed model is given in the supporting information section (S1 Appendix).
Ethical Clearance
A human subject research approval for this study was received from Institutional Review
Board (IRB) of the University of Gondar. As the study was retrospective, the IRB waived that
the research could be done based on record review without contacting the patients. Support
letter was obtained from the medical director office of the hospital for retrieving retrospective
data from the database and records. All the information was kept confidential, and no individ-
ual identifiers were collected.
Results
Baseline Description
Majority of the patients, 1462 (61.27%) were initiated with NVP containing Non-Nucleoside
Reverse Transcriptase Inhibitors (NNRTI); of whom 1023 (70.0%) used AZT as Nucleoside
Reverse Transcriptase Inhibitors (NRTI) backbones. Patients who were initiated with treat-
ment containing NVP were predominantly female 927 (63.41%) and were younger than 40
years were 1132 (77.43%). Among patients who were initiated with EFV containing treatment,
140 (15.2%) were ambulatory as compared to 124 (8.5%) who initiated with NVP containing
treatment. At initiation most patients, 1149 (48.2%) were at clinical stage III, of which 483
(52.3%) and 666 (45.5%) were initiated with EFV and NVP containing treatments respectively.
The median CD4 cell count was higher for those who were initiated with NVP as compared to
EFV (152 versus 141); however significant difference was not found with regard to age and
weight among the two treatment groups (Table 1). There was no significant difference between
EFV and NVP with regard to baseline CD4 cell counts, but association was observed with
other baseline covariates.
Description of composite treatment outcomes
The composite outcome was observed among 595(24.9%) patients with rate per 100 person
years of 12 (95%CI: 11.1-13.0). Amongst those who were initiated with NVP 370(25.3%)
patients experienced the events. Of these death, lost to follow up, NNRTI substitution, and dis-
continuation accounted for 99(26.8%), 122(33.0%), 137(37.0%), and 12(3.2%), respectively.
Whiles among those who were initiated with EFV 225(24.4%) experienced the event. Of these
death, lost to follow up, NNRTI substitution, and discontinuation accounted for 71(7.7%), 108
(11.07%), 37(4.0%) and 9(0.97%), respectively. A total of 818 (55.6%) and 515(55.7%) patients
stayed in their original regimen when initiated with NVP and EFV containing treatments
respectively. One-in-four patients who were initiated with NVP as NNRTI drug experienced
the event during the follow up period (Fig 1).
Analysis of time to composite treatment outcomes
The cohort was followed for a maximum of 61 months. The cumulative probability of staying
59 months was 82.7% and contributed a total of 4958.75 person-years of the data with mean
follow-up time of 25 (sd = 17.8) months. The rate of composite outcome was high during the
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first 10 months after ART initiation. The Kaplan-Meier survival curve for composite outcome
increased sharply after 40 months. Whereas the curve for death shows steady increase (Fig 2).
Log-rank test was used to test the difference between the categories of baseline covariates
with the probability of death. This test revealed the presence of significant difference among
the categories of baseline NNRTI, and NRTI drugs (Fig 3). The plots of other baseline covari-
ates were presented in S1 and S2 Figs.
The patients could experience more than one event during follow-up, and time to the first
event was used for analysis. In the primary analysis, only death was considered as an event of
interest. The risk of death was not different among patients on NVP compared with EFV
(AHR = 1.02 (95%CI: 0.81-1.58)) which was also observed in the log-rank test. Other baseline
covariates considered in the Cox-regression analysis were sex, age, NRTI backbone, WHO
staging, baseline CD4 cell counts, functional status and ART start years. In the adjusted analy-
sis, patients who were initiated with ART at old age (greater than 40 years) (HR = 1.65, 95%CI:
1.21-2.31), TDF backbone as compared to AZT (HR = 1.90, 95%CI: 1.35-2.67) and WHO
stage IV or III as compared to stage II or I (HR = 1.77, 95%CI: 1.22-2.56) had higher risk of
death. Whilst CD4 cell counts higher than 200 cell/mm3 (HR = 0.40, 95%CI: 0.25-0.64) and
functional status of working (HR = 0.51, 95%CI = 0.37-0.71) had reduced risk of death as com-
pared to ambulatory or bedridden (Table 2).
At baseline, patients who were lost to follow up had similar CD4 counts, age, WHO stage
and functional status as dead patients. Moreover, study showed that lost to follow up patients
Table 1. Cohort characteristics at initiation of ART by Non-nucleotide Reverse Transcriptase Inhibitor (NNRTI) of HIV/AIDS patients in Gondar Uni-
versity Hospital, Northwest Ethiopia, 2013.
Characteristic Efavirenz, n = 924 Nevirapine, n = 1462 P-value
Sex, n(%)
Female 497(53.8) 927(63.4) <0.0001
Male 427(26.2) 535(36.6)
NRTI backbone, n(%)
Zidovudine + lamivudine 215(23.3) 1,023(70.0) <0.0001
Tenofovir + lamivudine 657(71.1) 331(22.6)
Stavudine + lamivudine 52(5.6) 108(7.4)
Functional Status, n(%)
Ambulatory 140(15.2) 124(8.5) <0.0001
Bedridden 62(4.2) 24(1.6)
Working 722(78.1) 1,314(89.9)
WHO stage, n(%)
I 119(12.9) 390(26.7) <0.0001
II 101(10.9) 285(19.5)
III 483(52.3) 666(45.5)
IV 221(23.9) 121(8.3)
ART Start Year, n(%)
2009 247(26.7) 437(29.9) <0.0001
2010 190(20.6) 321(22.0)
2011 154(16.7) 285(19.5)
2012 128(13.8) 253(17.3)
2013 205(22.2) 166(11.3)
Age, median (IQR) 33(40-27) 31(38-27) 0.004
CD4 counts, median(IQR) 141(231-66) 152(210-84) 0.196
Weight (kg), median (IQR) 49(55-43) 50(58-45) 0.00017
doi:10.1371/journal.pone.0168323.t001
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PLOS ONE | DOI:10.1371/journal.pone.0168323 December 20, 2016 6 / 18
were often found to be dead when tracked [27]. Thus, sensitivity analysis was done by consid-
ering lost to follow up as event. Despite few changes, the effects of these covariates were similar
with the primary analysis. However, sex and d4t backbone were significant in the sensitivity
analysis, but not in the primary analysis. The risk of composite outcome was 1.30(95%CI:
1.07-1.58) times higher among males patients than the female patients. Whilst the hazard of
composite outcome was 1.73(95%CI: 1.22-2.46) and 1.89(95%CI: 1.50-2.38) times higher for
patients who initiated with d4t and TDF containing ART regimen respectively compared with
AZT.
Characteristics at baseline might be different for patients initiated with NVP or EFV con-
taining regimens. A secondary analysis was performed using a propensity score weighting of
the model. Covariates NRTI, age, gender, baseline functional status, WHO stage, and CD4 cell
counts were included in the propensity model. The continuous measure of propensity score
was used as an additional covariate in the final model. The results revealed that the risk of
death or composite outcome are not different among the NNRTI drugs which is consistent
with multivariate Cox-regression.
Comparison of Efavirenz versus Nevirapine on NRTI backbone. In order to compare
the risk of composite outcome on the two NNRTI drugs a Cox PH model was fitted adjusting
for NRTI backbones. On a backbone of d4t and AZT, there were no significant differences in
the risk of composite outcome between NVP and EFV after adjusting for other baseline
Fig 1. Schematic presentation showing study participants with their treatment outcomes assessed from January 2009 to
December 2013.
doi:10.1371/journal.pone.0168323.g001
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covariates (sex, WHO stage, functional status and ART start year). In a similar analysis for
TDF, the risk of composite outcome was 1.51(95%CI: 1.01-2.28) times higher on NVP as com-
pared to EFV.
Comparison of Zidovudine, Stavudine and Tenofovir on NNRTI drugs. Similarly,
NRTI backbones were compared using a Cox PH model adjusting for NNRTI drugs. In EFV
of an NNRTI option, the risk of composite outcomes on TDF and D4T were 1.83(95%CI:
1.36-2.47), and 1.70(95%CI: 1.11-2.61) respectively. Likewise patients who initiated with NVP
containing regimen, the hazard of composite outcomes on TDF and D4T were 2.09(95%CI:
1.38-3.18), and 0.97(95%CI: 0.46-2.04) respectively. Thus, there were significant differences in
the risk of composite outcomes on TDF as compared to AZT in both NNRTI drugs.
Longitudinal modeling of CD4 cell counts evolution. The cohort was followed for a
maximum of 61 months. The median number of repeated measurements was 4 (IQR = 2-5)
with a maximum of 10 measurements per patient. Time from ART initiation until first regi-
men change was considered for analysis presented in this paper. Note that models were fitted
to the logarithm of CD4 counts. An example of the CD4 counts for randomly selected individ-
uals are shown in Fig 4A. The observed individual profile with its mean plot showed an overall
increase in the level of CD4 cell counts over time as shown in Fig 4B. The rise was relativity
quick during the first 5 months since the start of ART and became steady after month 5. A
semi-parametric mixed effect model, which takes into account both the longitudinal aspect
Fig 2. Kaplan-Meier survival curves for death and composite outcome among HIV/AIDS patients at Gondar University Hospital,
2013.
doi:10.1371/journal.pone.0168323.g002
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and the subjects heterogeneity of the data was fitted. An elaborate discussion about the model
and model formulation are given in the methods section. The overall trend of the data is
shown in Fig 4C. In addition to the trend, the semiparametric mixed model allows the estima-
tion of the rate of change of CD4 counts (i.e. the first derivative). A derivative equal to zero
implies a constant trend with respect to time. The response of CD4 counts for ART treatment
clearly observed in Fig 4D which presents the rate of CD4 change over time. Note how the
derivative decreases sharply to zero in the first 10 months after the initiation of the ART treat-
ment and thereafter remain relatively stable and closed to zero.
Non-Nucleotide Reverse Transcriptase Inhibitor (NNRTI) drugs. The Semiparametric
mixed effects model also allows us to compare between different treatments. Fig 5 presents a
comparison between EFV and NVP. Regardless of the type of original regimen, log CD4 cell
counts started increasing immediately after initiation of ART. This can be clearly seen in
Fig 5A and 5B which show the predicted trend and the rate of change over time, respectively.
For both treatments, a sharp increase is observed in the first 10 months after initiation of ART.
Further, Fig 5C and 5D show the difference between the two treatments in both estimated log
CD4 trend and the rate of change in log CD4 counts. A curve for which the 95% confidence
band covers the value of zero indicates that the difference is not statistically significant. Fig 5C
and 5D reveal that the response for the two NNRTI drugs seems to be differ only in the first
Fig 3. Kaplan-Meier survival plots. The proportion of surviving was plotted at anytime for NNRTI and NRTI groups at initiation and
compared by log-rank test among HIV/AIDS patients at Gondar University Hospital, 2013.
doi:10.1371/journal.pone.0168323.g003
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few months after initiation of ART and thereafter the treatments are not statistically different
in both CD4 count levels and the rate of change since the 95% confidence bands cover the
value of zero in both cases.
Nucleotide Reverse Transcriptase Inhibitor (NRTI) backbone. The trend of log CD4
cell counts was estimated for the three NRTI backbones (AZT, d4t and TDF). Fig 6A and the
upper panels in Fig 7 show that, 10 months after the initiation of the treatment, patients treated
with d4t reached higher levels of log CD4 counts compared to the patients that were treated
with AZT and TDF as the backbones. Note that from 10 months after the initiation of the
treatment the rate of change in log CD4 counts is the same for all backbones (see Fig 6B and
the lower panels in Fig 7).
Discussion
The Scaled-up of antiretroviral therapy has shown to be effective in improving quality of life,
reducing morbidity and mortality, and increase productivity in patients infected with HIV.
However, there is a need to better understand the characteristics of long-term outcomes of
treatment combinations. The main aim of this study was to determine and compare the long-
term response of patients on NVP or EFV based first line ART regimen in Northwest Ethiopia.
The analysis presented in this paper was focused on a hospital data and the methodology
Table 2. Cox-regression analysis of factors associated with the composite outcome of treatment failure on first-line ART in Northwest Ethiopia,
2013.
Covariate Primary analysis (lost as censored) Sensitivity analysis(lost as event)
UHR(95%CI) AHR(95%CI) p-value UHR(95%CI) AHR(95%CI) p-value
Sex, n(%)
Female 1 1 1 1
Male 1.18(0.88-1.57) 0.97(0.72-1.31) 0.85 1.39(1.25-1.68) 1.30(1.07-1.58) 0.007
Age
<40 years 1 1 1
40 years 1.66(1.23-2.24) 1.65(1.21-1.31) 0.001 1.12(0.90-1.39) 1.02(0.81-1.27) 0.88
NNRTI
Efavirenz 1 1 1 1
Nevirapine 0.75(0.56-0.99) 1.19(0.85-1.65) 0.29 0.65(0.54-0.79) 1.02(0.81-1.58) 0.88
NRTI backbone
Zidovudine 1 1 1 1
Stavudine 1.71(0.99-2.95) 1.20(0.68-2.12) 0.52 2.21(1.58-3.10) 1.73(1.22-2.46) 0.002
Tenofovir 2.20(1.62-2.98) 1.90(1.35-2.67) .0001 2.19(1.78-2.69) 1.89(1.50-2.38) <.001
WHO stage
I and II 1 1 1 1
III and IV 2.30(1.62-3.27) 1.77(1.22-2.56) .0002 1.81(1.45-2.26) 1.37(1.08-1.74) 0.008
Base CD4 cells
<200 cells/mm3 1 1 1 1
200 cells/mm3 0.33(0.21-0.52) 0.40(0.25-0.64) .0001 0.67(0.52-0.85) 0.79(0.62-1.01) 0.05
Functional status
Ambulatory/Bedridden 1 1 1 1
Working 0.35(0.26-0.48) 0.51(0.37-0.71) <.01 0.40(0.32-0.49) 0.53(0.42-0.66) <.001
ART start Year
Before 2010 1 1 1 1
Since 2010 0.67(0.50-0.91) 0.88(0.65-1.21) 0.44 0.81(0.65-0.98) 1.01(0.82-1.25) 0.93
doi:10.1371/journal.pone.0168323.t002
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presented in the paper can be applied routinely to similar dataset from other treatment centers.
We have shown that treatment responses were comparable whether NVP or EFV was chosen
to initiate ART for HIV-positive patients in Gondar Hospital, Ethiopia. Statistical significant
difference was not detected in the risk of death or composite outcome among patients who ini-
tiated with the two NNRTI drugs after adjusting for baseline covariates. This is in agreement
with other studies conducted in central Ethiopia [19], Ghana [21] and Botswana [28] which
indicated a non-significant difference in the long-term effectiveness of EFV and NVP based
ART regimens in the population. However, it is in contrast with findings from observational
study by ART Cohort Collaboration (ART-CC) [29] and HIV-CAUSAL collaboration [17, 30]
in which patients who initiated with NVP containing regimen has an increased risk of treat-
ment failure as compared to EFV. A systematic review also revealed that EFV based first line
ART is a preferred NNRTI drug in first line treatment regimen for HIV treatment as it has
lower risk for treatment failure [31].
There was significant difference in the risk of composite outcomes between patients who
were initiated with TDF containing ART regimen and those with AZT after controlling for
NNRTI drugs. The risk on composite outcome for TDF when combined with NVP is two
Fig 4. Log CD4 counts over time. (A) Individual log CD4 count trajectories of 5 selected patients, (B) Individual log cd4 count
trajectories with observed average plot, (C) individual log cd4 count trajectories with predicted CD4 count trend (by the semi-parametric
mixed effects model) and (D) the estimated rate of change (the first derivative) over time.
doi:10.1371/journal.pone.0168323.g004
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times higher as compared to AZT. This was supported by studies in, Zambia [22], Nigeria [32]
and France [33] in which TDF containing regimen was associated with higher mortality and
virologic failure. In contrast with our study, studies conducted in South African [34] and
Botswana showed as TDF appeared to perform better than AZT with lower mortality. In the
adjusted analysis the risk of composite outcome on TDF backbone has increased by 50% on
NVP as compared to EFV indicating that TDF is more effective when administered with EFV
than NVP. This is in line with finding from Thailand [35] in which the frequency of TDF-
associated renal impairment was significantly higher in patients receiving TDF plus NVP com-
pared to TDF plus EFV regimen.
This study also showed that there was a 73% increased risk of composite outcome for
patients who were initiated with d4t containing regimen as compared to AZT containing regi-
men. The risk of composite outcome was 70% and 72% higher on d4t as compared to AZT for
NVP and EFV, respectively. This was supported by a study conducted in Cameron [36] in
which patients initiated with d4t has increased risk of toxicity. However, this finding was con-
tradicted with the results reported by a study conducted in Kenya [37] in which d4t has a
decreased risk of treatment failure as compared to AZT. The risk of composite outcomes was
Fig 5. Response of log CD4 cell counts for two NNRTI drugs (efavirenz and nevirapine). (A) individual and average profiles, (B) rate
of change over time for CD4 counts, (C) Estimated difference between the trend for efavirenz and nevirapine. Whenever the 95%
confidence band for the curve (the gray area) covers the value of zero the difference between the two treatment is not significant.
doi:10.1371/journal.pone.0168323.g005
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not statistically significant on d4t with any of the NNRTI drugs when lost patients were
assumed censored. This indicated that the difference in risk on composite outcome on d4t ver-
sus AZT was due to lost to follow up cases. The risk of composite outcome was higher among
patients who initiated ART at clinical stage 3 or 4, low CD4 count and ambulatory or bedrid-
den functional status during ART initiation which is inline with other studies [38, 39].
Results from S3 Appendix revealed that TDF has higher risk despite the types of events as
compared to AZT which is consistent with other studies [22, 33]. Although the effect of d4t
and AZT on death and NNRTI modification was the same, statistical significant difference was
observed on lost to follow up. Those patients who initiated with d4t containing regimen had
about two fold risk of lost to follow up as compared to those who initiated with AZT contain-
ing regimen. This might be due to the long-term irreversible side effects of d4t [8]. Patients
who initiated with NVP had 2.5 times higher risk of modifying the NNRTI drug than those
patients who initiated with EFV. Initiating with TDF of NRTI backbone has also higher risk of
NNRTI modification than those who initiated with AZT. This is in contrast with finding of the
study in South Africa [40] in which rate of substitution was lower among those who initiated
with TDF than AZT or d4t.
Fig 6. Individual and average profile plots of NRTI backbons. (A): Fitted individual and mean plots for each backbone. (B): Estimated
rate of change for each backbone and 95% confidence band.
doi:10.1371/journal.pone.0168323.g006
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In Ethiopia, like other resource-limited countries, CD4 cell counts are used as a main surro-
gate marker of treatment response due to the fact that viral load monitoring is not easily acces-
sible. We proposed a semi-parametric mixed effects model for the longitudinal evolution of
CD4 cell counts in order to investigate response to treatment based on individual and average
profile plots. There was an overall increase in CD4 cell counts over time which is consistent
with other studies [41–44]. As shown by the first derivative plot, the rate of CD4 increase in
response of treatment was high during the first 10 months and stabilized later. This analysis
also revealed that there was no difference in the trend of CD4 counts in the long-run among
patients who initiated with EFV or NVP containing regimen which is inline with previous
study conducted in Ghana [18]. Considering only the NRTI backbones, there was difference in
the evolution of log CD4 cell counts which is consistent with the study in Italy [45]. Even
though d4t is less preferable by clinicians, it has better effect in improving CD4 cell counts
than AZT and TDF which is supported by other study [46]. In the long run, the improvement
of CD4 level was better among patients who initiated with TDF containing regimen. Even
though d4t together with NVP was the combination at initiation of treatment which offer bet-
ter performance in increasing CD4 cells during the first 10 months since initiation, the rate of
Fig 7. Estimated pairwise difference between the NRTI backbones. Upper panels: estimated difference between the CD4 trend over
time for each pair of backbone. Lower panels: estimated difference of the rate of change of CD4 counts for each pair of backbones.
doi:10.1371/journal.pone.0168323.g007
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increase was not as good as the other combinations. All options of original regimen have simi-
lar effect between month 20 and 50. The results obtained from the semi-parametric mixed
effect model can be affected by the different time to lost to follow up or death reported in this
paper. A joint model for CD4 counts and time to composite outcome is currently under devel-
opment and will be reported in a future publication.
The main limitation of this study was the unmeasured variables effect on the findings of the
study. Since the study is based on retrospective data, many covariates were not measured.
Some of the variables which were not measured includes nutritional status of the patients,
adherence, opportunistic infections, viral load, side effects and reasons of regimen change.
This could affect the findings of this study. Another limitation was the definition of treatment
failure as composite outcome which is broad. This might overestimate the event which makes
comparison with other findings difficult. So, the result of this study should be interpreted with
insight of these limitations.
In conclusion, the study revealed that the long-term treatment outcomes did not depend on
NNRTI groups of the regimen. The outcomes of EFV containing regimen is comparable with
NVP containing regimen. However, difference was observed for NRTI backbones chosen to
initiate the treatment of HIV-infected patients in Ethiopia. The response of CD4 counts to
treatment was high during the first 10 months and stable then after. Further clinical study is
warranted in resource limited settings to investigate the effect of EFV and NVP on long-term
outcomes.
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